(资料图)
中信建投5月17日研报认为，仿制药集采不再一面倒，边际利好初现。创新药逐步兑现带来新增量。仿制药企业进行创新转型在近几年成果涌现创新转型的仿制药企值得关注。创新转型的仿制药企业具备仿制药业绩稳定，创新药利好持续兑现的特点，看好（1）传统产品集采出清，（2）创新药产品接近收获期，（3）创新药管线丰富，未来续航能力强，（4）存在出海可能的创新转型的仿制药企业。
（文章来源：界面新闻）
(资料图)
中信建投5月17日研报认为，仿制药集采不再一面倒，边际利好初现。创新药逐步兑现带来新增量。仿制药企业进行创新转型在近几年成果涌现创新转型的仿制药企值得关注。创新转型的仿制药企业具备仿制药业绩稳定，创新药利好持续兑现的特点，看好（1）传统产品集采出清，（2）创新药产品接近收获期，（3）创新药管线丰富，未来续航能力强，（4）存在出海可能的创新转型的仿制药企业。
（文章来源：界面新闻）
2023-05-17
2023-05-17
2023-05-17
2023-05-17
2023-05-17
2023-05-17
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-16
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-15
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-14
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13
2023-05-13